Please login to the form below

White paper for download: Real-world evidence: Hurdles and the holy grail

Real-world evidence and real-world data is a hot topic in market access today. Conferences, publications and studies are all focussing on the opportunities and benefits they bring. It’s also becoming a big area of investment for pharma, biotech and life science companies.

To ensure we make the most of real-world evidence and data, we need to first prepare for the hurdles that they present, and find solutions to overcome them, in order to reap the benefits they bring. Which is why we’ve written this white paper to help put you on the path to reaching the holy grail.

Download the white paper now for insight into:

  • real-world challenges
  • common misconceptions
  • how real-world evidence can enhance your strategy

Download the white paper here: https://www.validinsight.com/resource-center/white-paper-real-world-evidence-hurdles-and-the-holy-grail/

3rd September 2019

Share

Tags

Company Details

Valid Insight

+44 (0) 20 3750 9833

Contact Website

Address:
152-160 City Road
Kemp House
London
EC1V 2NX
United Kingdom

Latest content on this profile

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement.
Valid Insight
The 'winner takes all' pricing game
Tendering has long been common in healthcare for medical devices and diagnostics; the Gulf Cooperation Council and the Jamaica Commodity Trading Company have been using pharmaceutical tendering since the 1970s. In the 1990s, international institutions such as the World Health Organisation and the World Bank endorsed tendering as the preferred procurement process for drugs.
Valid Insight
RWE Blog 4: The place of real-world evidence in the market access strategy
The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in Real-world challenges and real-world data, understanding the payer's perspective, in Payers use real-world data cautiously, and seeing the views of both advocates and opponents of RWE in Is real-world evidence the holy grail: Finding the balance.
Valid Insight
RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use real-world data cautiously. In our third instalment, we’re looking at how to find the right balance in using RWE.
Valid Insight
RWE Blog 2: Payers use real-world data cautiously
Following our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in our blog Real-world challenges and real-world data, the second instalment of our four-blog series looks at why payers use real-world data cautiously.
Valid Insight
RWE Blog 1: Real-world challenges and real-world data
This is the first of a set of four blogs on real-world data (RWD) and real-world-evidence (RWE), and their role in market access.
Valid Insight